Abstract
A detailed analysis of renal monitored indicators suggest that treatment with empagliflozine has favorable implications in relation to the risk of kidney failure, respectively. alter their function. The results are very useful, if we relate it to the file that was included in the study EMPA-REG OUTCOME - for patients with diabetes in secondary prevention, with a long course of the disease and usually treated with insulin.